Short Interest in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Increases By 6.9%

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) was the recipient of a significant increase in short interest in April. As of April 15th, there was short interest totalling 20,100 shares, an increase of 6.9% from the March 31st total of 18,800 shares. Currently, 0.2% of the shares of the stock are short sold. Based on an average trading volume of 5,600 shares, the days-to-cover ratio is currently 3.6 days.

Anebulo Pharmaceuticals Trading Up 2.1 %

ANEB stock opened at $2.96 on Thursday. The firm has a 50-day moving average price of $2.75 and a 200-day moving average price of $2.50. Anebulo Pharmaceuticals has a 12 month low of $1.62 and a 12 month high of $4.05. The stock has a market capitalization of $75.87 million, a P/E ratio of -7.05 and a beta of -1.00.

Anebulo Pharmaceuticals (NASDAQ:ANEB) last released its quarterly earnings data on Tuesday, February 13th. The company reported ($0.11) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.11). As a group, equities analysts predict that Anebulo Pharmaceuticals will post -0.47 EPS for the current fiscal year.

Anebulo Pharmaceuticals Company Profile

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.